Charco Neurotech

Charco Neurotech operates at the intersection of medical devices, digital health, neurology, and wearables, with a narrow focus on Parkinson’s disease. Its core offering is differentiated by combining a non-invasive wearable form factor with pulsed cueing and high-frequency focused vibrotactile stimulation, rather than relying on implanted systems or medication changes. The CUE Device and companion CUE App are designed to support movement, personalize stimulation settings, provide medication reminders, and track symptoms. This gives the company a potentially accessible position between conventional clinical interventions and general-purpose consumer wearables. The business also emphasizes collaboration with clinicians, researchers, and people living with Parkinson’s, which supports an evidence-led product narrative. However, the available profile does not identify named direct competitors or provide comparative clinical, regulatory, reimbursement, or commercial metrics. Its competitive standing therefore cannot be ranked precisely against other Parkinson’s device developers. With approximately $9.9 million in disclosed funding and a Cambridge base, Charco appears to remain an early-stage specialist rather than a scaled medical-device platform.

Charco Neurotech’s trajectory shows progression from a 2019 founding to a two-round seed financing history, including a disclosed $9.9 million round announced on Nov 16, 2021. Amadeus Capital Partners and Parkwalk Advisors led that financing, joined by investors including Crista Galli Ventures, UTEC, and Mint Venture Partners. The company has since expanded its operating structure to at least five featured positions spanning operations, medical leadership, strategy, data, and clinical advice, while its employee band remains between 11 and 50 people. Product development has broadened from the CUE Device to the CUE App and website-described CUE1 and CUE1+ devices, creating a hardware-and-software model rather than a standalone wearable. A 2024 patent application suggests continued investment in the underlying device approach, while the 2024 WIRED coverage and Parkinson’s fundraising sponsorship increased external visibility. The 2026 Cambridge media mentions suggest the company remains active and regionally notable, but there is no disclosed post-2021 funding, valuation, major launch, or verified employee-growth figure.